Michael Postow
Chief, Melanoma Service · New York Presbyterian Hospital
Credentials: · · · ·
History
PresentMelanoma Service Division · New York Presbyterian Hospital
- Present
Melanoma Disease Management Team · New York Presbyterian Hospital
2012–2014
Research
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 6,426 citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Review · New England Journal of Medicine · 2018 · First of 3 authors · 3,894 citations
Genetic basis for clinical response to CTLA-4 blockade in melanoma
New England Journal of Medicine · 2014 · 3,502 citations
93 papers
64 papers · 11 as a fellow
- AS
41 papers · 13 as a fellow
32 papers
- PM
24 papers · 8 as a resident
23 papers · 6 as a fellow
22 papers
20 papers
Clinical trials
- 2022–2027
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2017–2027
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2017–2025
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
- 2010–2016
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center